Monoclonal antibodies are highly specific and powerful reagents which have proved invaluable in mapping the distribution and dissecting the function of cell-surface antigens, especially on cells of the immune system, and are finding an increasing use in clinical medicine. ' The murine anti-CD3 monoclonal antibody known as OKT3, with specificity for a cell-surface antigen found on T-lymphocytes, is widely used to reverse corticosteroid-resistant renal allograft rejection episodes and a variety of other antibodies are currently under trial in clinical transplantation studies. Murine monoclonal antibodies directed against human T-cells have already been used as adjuncts to topical corticosteroids in attempts to reverse clinical corneal graft rejection. 23 As well as having actual or potential uses as immunosuppressive agents in transplantation, monoclonal antibodies can help biologists to understand the underlying mechanisms of graft rejection. One of the more interesting areas of current research concerns the nature of the T-cell that is involved in graft rejection. CD4-positive T-cells, restricted by major histocompatibility complex (MHC) class II antigens, are predominantly involved in helper cell and delayed-type hypersensitivity (DTH) responses, whereas CD8-positive T-cells, restricted by MHC class I antigens, are predominantly involved in cytotoxic cell and suppressor cell responses. The type of T-cell that will accumulate in a rejecting graft is likely to depend to some extent on the type of MHC antigen disparity between donor and host, and both CD4-and CD8-positive T-cells have been observed in rejecting corneal grafts. However, identification of the major subset of T-cells accumulating in mismatched grafts should allow therapy directed against specific effector cells to 'be targeted more precisely.
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